Unfortunately, though proven novel effective anticancer therapies in several cancers, programmed cell death protein 1 (PD-1) inhibitor (nivolumab) and anti-PD-L1 antibody (avelumab) showed limited benefits in improving survival outcomes for GC patients (93, 94). The gene discussed is PDCD1; the disease is gastric cancer.